- Approval makes Xolair the only biologic for children ages six and up with uncontrolled allergic asthma
 - Asthma is one of the most common long-term diseases in children, affecting about 6.3 million people younger than 18 in the U.S.
 - More than 200,000 allergic asthma patients have been treated with Xolair since its approval in 2003 for people 12 years and older3
 
Catalyst
          Slingshot members are tracking this event:
          
        FDA Approves Genentech’s Xolair (omalizumab) for Allergic Asthma in Children
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance 
        
  | 
      Impact on Stocks
         | 
    ||||
|---|---|---|---|---|---|---|
| RHHBY | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
          
            Catalyst Date
          
            
                Occurred on: 
    Jul 07, 2016
 
 
          
          
    Related Projects 
      
  
  - 
          
Don’t see a project related to the catalyst you care about?
 
            Related Keywords
            
    Omalizumab, Xolair, Allergic Asthma